A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients With Metastatic Renal Cell Carcinoma.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Best Overall Response Rate (complete and partial response rate)
During study treatment or within 30 days after termination of active therapy
Bayer Study Director
United States: Food and Drug Administration